This trial is evaluating whether Iron in infant formula will improve 1 primary outcome and 6 secondary outcomes in patients with Infant Development. Measurement will happen over the course of at baseline (birth) and end of intervention (4 months).
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Iron In Infant Formula is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Infants have their own unique way of development. We will see their growth in the womb, the process of birth, infancy and adolescence, and their development and ways of thinking and behaving. It is important to understand infants' development as we work to improve our services and treatment for babies, children and adults with disabilities and developmental disability. We are learning more about the developing brain through modern research that looks into brain imaging and medical testing. This is an exciting new area of study. The goal of this research is to understand what is going on in the developing brain as we observe them from birth, through to adolescence and even adulthood. Our research will give us new insights into how children develop and the causes of development.
The signs of infant development included delayed breast feeding, breast feeding difficulties, feeding solids earlier than usual, and vomiting. The signs are most likely attributable to early or insufficient care.
Although the developmental processes of infants can be measured in different ways, we see the different perspectives as representing a unified picture of the underlying biological factors that shape the development of their cognitive, emotional and motor systems. The developmental processes include not only the development of brain, but also the development of the body's endocrine and immune systems, which affect the brain functioning. Because the brain of infants is still developing in many aspects but the brain structures are more similar to adults than other animals, it is important that we know how the brain develops in the early stages of postnatal life.
Infants can be diagnosed with neurodevelopmental disorders in the first and second months of life. These interventions are based on developmental research and supported by the [International Infant Developmental Symposium] (http://www.iisd.org/). Physicians can [participate in the meetings of the symposium and/or attend the general program] for more information on interventions that meet the developmental needs of infants and toddlers.
Each year, around 7 million US infants will be born. It is likely that many more infants will develop problems during this time. The US infant is a growing health concerns. The National Institute of Child Health and Human Development has developed an infant developmental monitoring program which could help identify infants at risk of later developmental problems.
Many families with children with developmental delays, including those with autistic spectrum disorder, find that a team of professionals can help get the child ready and functioning at optimum levels in the community. The following sections will address the different types of therapy that have been shown to be extremely effective in helping children with developmental delays, and will review some of the specific treatment paradigms used in these cases.
The conclusions of this study have practical implications for both practitioners and parents. Parents of formula fed infants could benefit from further iron supplementation. Practitioners also could benefit from further studies into the usefulness and cost-effectiveness of iron supplementation.
Developmental outcomes at ages 18months and four years show no strong evidence of intrafamilial effects. The evidence of shared environmental factors is strongest when comparing the two measures across children in the same family.
Infant formulas should contain iron, but the amount and the source of iron in iron supplements are both important questions for mothers. [What is iron in formula? A review. J Pediatr Surg 36:1045-1046 (2005); Clinical and Laboratory Diagnosis of Infestation with Group A Streptococcus in Infants.
[Formula_1<nowiki>'s</nowiki> composition was comparable with the current US Recommended Dietary Allowance of iron (RIAL) (19 mg/day, 18 IU/mL) in breast milk (19 mg/day, 22 IU/mL) but differed from the World Health Organization (WHO) minimum threshold amount requirements (18 mg/day, 17 mg/L) for adult women. Formula_1 contained in excess of the RIAL is a risk factor for children < 2 years of age, even in the presence of breast-feed].
The current data suggest that the principal underlying mechanism of infant neurobehavioral development is one of the developmental disturbances of the hypothalamic–pituitary–adrenomedullary axis (HPA axis) which is associated with neurodevelopmental disturbances.
Age of diagnosis for infant developmental delays ranges from infancy to preschool age. As for individuals with infantile development delays, children are most likely to be diagnosed between 2 and 4 years old. Those with infant developmental delays in school age range from 5 to 10 years.